Regeneron Pharmaceuticals (REGN) Deferred Taxes (2013 - 2026)

Regeneron Pharmaceuticals' Deferred Taxes history runs 14 years deep, the most recent figure standing at $96.0 million for Q1 2026.

• On a quarterly basis, Deferred Taxes fell 30.98% year-over-year to $96.0 million in Q1 2026; TTM through Mar 2026 was $742.3 million, a 5.14% increase from a year earlier, with the FY2025 full-year figure at $785.4 million, up 3.71% from the prior year.
• Deferred Taxes fell to $96.0 million in Q1 2026 per REGN's latest filing, from $232.5 million in the prior quarter.
• Across five years, Deferred Taxes topped out at $286.3 million in Q4 2023 and bottomed at $85.7 million in Q3 2022.
• The 5-year median for Deferred Taxes is $190.4 million (2024), against an average of $189.6 million.
• Across the five-year window, Deferred Taxes jumped 2327.72% in 2022 and tumbled 43.57% in 2024, its largest moves.
• Year by year, Deferred Taxes stood at $279.7 million in 2022, then climbed by 2.36% to $286.3 million in 2023, then retreated by 2.13% to $280.2 million in 2024, then declined by 17.02% to $232.5 million in 2025, then slumped by 58.71% to $96.0 million in 2026.
• Per Business Quant, the three latest REGN Deferred Taxes figures stand at $96.0 million (Q1 2026), $232.5 million (Q4 2025), and $278.6 million (Q3 2025).